top of page

With key EHA data coming up, Shattuck Labs looks to build on its hypothesis that adding an immune agonism component will transform the SIRPα space

  • May 24, 2024
  • 1 min read

Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is needed to succeed in the SIRPα (CD47) approach to oncology.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page